Data Shows a Single Application of PriMatrix Closed More Wounds Than Standard of Care Alone PRINCETON, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, today announced positive clinical outcomes for

Contract awarded for products that bring improvement to healthcare industry PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, announced its SurgiMend ® Collagen Matrix for Soft Tissue

PRINCETON, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2021 financial results on Wednesday, July 28, 2021 prior to market open.

Peter Arduini to serve as President and CEO through the end of 2021 Candidate search launched to identify successor PRINCETON, N.J., June 24, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced that Peter

PRINCETON, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will host an Investor Day meeting from 8:30 a.m. to approximately 12:30 p.m. ET, today May 20, 2021.

PRINCETON, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will host an Investor Day meeting from 8:30 a.m. to approximately 12:30 p.m., U.S. eastern time on May 20, 2021.

PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2021. First Quarter 2021 Financial Summary Reported revenues were $360.1

PRINCETON, N.J., April 19, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company and manufacturer of SurgiMend Collagen Matrix, today issued the following statement regarding the U.S.

PRINCETON, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2021 financial results on Wednesday, April 28, 2021 prior to market open.

PRINCETON, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (Nasdaq:IART), a leading global medical technology company, today announced the appointment of Shaundra Clay to its board of directors, effective today. “We are delighted to welcome Shaundra, a seasoned

PRINCETON, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in the following investor conferences: On February 24, 2021, Carrie Anderson, executive vice president

PRINCETON, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full-year ended December 31, 2020, consistent with its preliminary revenue results announced on January 14, 2021.

PRINCETON, N.J., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it completed the previously-disclosed acquisition of ACell, Inc. “Acquiring ACell and its proprietary MatriStem UBM™ technologies

PRINCETON, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2020 revenue results. Preliminary Fourth Quarter and Full-Year 2020

PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has completed its previously announced divestiture of its Extremity Orthopedics business to Smith+Nephew (LSE:SN, NYSE:SNN).